Cytokinetics EVP exercises options, sells 3,500 shares
CYTOKINETICS EVP of R&D exercised options and sold 3,500 shares in a Rule 10b5-1 planned trade.
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) reported that executive vice president of research and development Fady Ibraham Malik exercised options for 3,500 shares of common stock on September 8, 2026 at an exercise price of $7.80 per share and received 3,500 shares of common stock. On the same date, he sold 3,500 shares of common stock at $75.46 per share in a reported sale. Following the option exercise, he held 26,886 derivative option-based shares directly. The company indicates these transactions were carried out under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,500 shares ($237K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Malik Fady Ibraham
Role
EVP Research & Development
Sold
3,500 shs ($264K)
Approx. gross sale proceeds
$264K
Approx. exercise cost
$27K
Approx. pre-tax spread
$237K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 3,500 | $75.46 | $264K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 26,886 contracts (Direct);
Common Stock — 153,902 shares (Direct)
Key Figures
Options exercised: 3,500 shares
Exercise price: $7.80 per share
Shares acquired from exercise: 3,500 shares
+5 more
8 metrics
Options exercised
3,500 shares
Non-qualified stock options for common stock exercised on September 8, 2026
Exercise price
$7.80 per share
Exercise price of non-qualified stock options on September 8, 2026
Shares acquired from exercise
3,500 shares
Common stock received from option exercise on September 8, 2026
Shares sold
3,500 shares
Common stock sold on September 8, 2026
Sale price
$75.46 per share
Price per share for common stock sold on September 8, 2026
Derivative holdings after exercise
26,886 shares
Directly held option-based derivative securities after the reported exercise
Option expiration date
February 27, 2028
Expiration of the non-qualified stock option series exercised in part
Option grant exercise date
March 27, 2018
Original exercise start date associated with the option series
Key Terms
Non-Qualified Stock Option, derivative security, Rule 10b5-1 trading plan
3 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Rule 10b5-1 trading plan regulatory
"transactions were carried out under a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did CYTK report for EVP R&D Fady Ibraham Malik on September 8, 2026?
CYTOKINETICS INC reported that Fady Ibraham Malik exercised options for 3,500 shares of common stock at $7.80 per share and sold 3,500 shares of common stock at $75.46 per share on September 8, 2026, in direct ownership accounts.
At what price did the CYTK executive exercise stock options on September 8, 2026?
On September 8, 2026, Fady Ibraham Malik exercised non-qualified stock options for 3,500 shares of CYTOKINETICS common stock at an exercise price of $7.80 per share, converting a derivative security into directly held common stock.
Did the CYTK insider transactions occur under a Rule 10b5-1 trading plan?
Yes. The company indicates that the reported transactions for Fady Ibraham Malik on September 8, 2026 were conducted under a Rule 10b5-1 trading plan, meaning the trades were made pursuant to a pre-arranged trading arrangement.
What derivative holdings did the CYTK executive report after the option exercise?
After exercising options on September 8, 2026, Fady Ibraham Malik reported direct holdings of 26,886 shares in the form of derivative option-based securities, reflecting remaining non-qualified stock options following the exercise of 3,500 option shares.
What is the role of the reporting person in CYTOKINETICS (CYTK)?
The reporting person, Fady Ibraham Malik, serves as executive vice president of research and development at CYTOKINETICS INC, and the Form 4 discloses his option exercise and share sale activity in the company’s stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
